Skip to main content
. 2023 Mar 3;13:1097911. doi: 10.3389/fonc.2023.1097911

Figure 2.

Figure 2

Kaplan–Meier curves. (A) PFS in the fruquintinib group and regorafenib group. (B) OS in the fruquintinib group and regorafenib group. mPFS, median progression-free survival. mOS, overall survival.